Technological Advances Propel Medical Exoskeleton Demand

According to the latest market research study published by P&S Intelligence, the global medical exoskeleton market was valued at USD 485.8 million in 2023 and is projected to experience a remarkable CAGR of 44.8% from 2024 to 2030, reaching an estimated USD 6,336.8 million by 2030. This substantial growth is primarily driven by the increasing number of individuals with physical disabilities, a rising geriatric population, and a growing number of orthopedic surgeries. According to the World Health Organization (WHO), approximately 1.3 billion people, or one in six globally, experience significant disability.  

Additionally, the market is influenced by the rising incidence of neurological diseases, such as ataxia, Parkinson’s disease, amyotrophic lateral sclerosis, acute spinal cord injury, and Alzheimer’s disease. These conditions often result in the loss of control and coordination of physical movements, thereby increasing the demand for medical exoskeletons. Furthermore, the growing number of road accidents, severe injuries, and strokes contributes to the market's expansion. The WHO reports that approximately 1.3 million people die each year due to road traffic crashes, highlighting the need for advanced rehabilitation solutions.

Download free Reports Sample Now

Key Insights

Segmentation Analysis:

·        Component: In 2023, hardware components accounted for 60% of the market share, owing to the essential role of sensors, powered systems, actuators, and control systems in exoskeletons. The hardware segment is expected to grow at a CAGR of 45.0% during 2024–2030. Software components are anticipated to grow at a CAGR of 45.2% in the same period, driven by the integration of artificial intelligence (AI) to enhance exoskeleton functionality.

·        Type: Powered exoskeletons held a larger market share in 2023, attributed to recent technological advancements. For instance, Stanford University, with funding from the National Institutes of Health (NIH), developed an exoskeleton that adapts rapidly to users’ movements during normal walking. Key industry players are focusing on integrating AI to boost human potential and device productivity. For example, in December 2021, German Bionic launched the fifth generation of Cray X, featuring active walking assistance and a new energy management system. ​

Regional and Geographical Trends:

North America is expected to dominate the medical exoskeleton market during the forecast period, driven by advanced healthcare infrastructure, high adoption rates of innovative technologies, and supportive government initiatives. Europe is projected to follow, with significant growth anticipated in the Asia-Pacific region due to increasing healthcare investments and a rising geriatric population.

Technological Advancements Shaping the Market:

The integration of AI and machine learning into medical exoskeletons is enhancing their adaptability and efficiency. For example, Blackrock Neurotech partnered with Phantom Neuro to develop the Phantom X system, enabling patients to control assistive devices like exoskeletons and prosthetics in real-time. Additionally, Ekso Bionics Holdings Inc. received FDA clearance for EksoNR for rehabilitative use in multiple sclerosis patients, expanding its application beyond stroke and spinal cord injury rehabilitation. ​

Competitive Dynamics, Major Players, and Emerging Opportunities:

The medical exoskeleton market is characterized by intense competition, with key players focusing on technological innovations and strategic partnerships to strengthen their market positions. Emerging opportunities include the development of lightweight, affordable exoskeletons and expanding applications in rehabilitation centers and home care settings. Companies are also exploring untapped markets in developing economies, aiming to cater to the growing demand for advanced mobility solutions.

In conclusion, the medical exoskeleton market is poised for substantial growth, driven by technological advancements, increasing prevalence of disabilities, and a rising aging population. Stakeholders are actively investing in research and development to introduce innovative products, aiming to improve patient mobility and quality of life.